Psychological Effects of a Suspicious Prostate Cancer Screening Test Followed by a Benign Biopsy Result
Overview
Authors
Affiliations
Purpose: To evaluate the psychological implications of an apparently false-positive screening result for prostate cancer.
Methods: The sample comprised 167 men with a benign biopsy result in response to a suspicious screening test result (biopsy group) and 233 men with a normal prostate-specific antigen (PSA) test result (control group). The men responded to a questionnaire within about 6 weeks of their biopsy or PSA results. They were asked about demographic characteristics, medical history, psychological effects, biopsy experience, and prostate cancer knowledge.
Results: The survey response rate was 85% (400/471). The mean (+/- SD) age of respondents was 60 +/- 9 years (range, 40 to 88 years); 88% (n = 350) were white. Forty-nine percent (81/167) of men in the biopsy group reported having thought about prostate cancer either "a lot" or "some of the time", compared with 18% (42/230) in the control group (P < 0.001). In addition, 40% (67/167) in the biopsy group reported having worried "a lot" or "some of the time" that they may develop prostate cancer, compared with 8% (18/231) in the control group (P < 0.001).
Conclusion: Men who underwent prostate biopsy more often reported having thought and worried about prostate cancer, despite having received a benign result. This underrecognized human cost of screening should be considered in the debate about the benefits and harms of prostate cancer screening.
Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened.
Aziz Z, Wagner S, Agyekum A, Pumpalova Y, Prest M, Lim F JAMA Netw Open. 2023; 6(11):e2343392.
PMID: 37971743 PMC: 10654798. DOI: 10.1001/jamanetworkopen.2023.43392.
Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer.
Gogola S, Rejzer M, Bahmad H, Alloush F, Omarzai Y, Poppiti R Cancers (Basel). 2023; 15(5).
PMID: 36900412 PMC: 10000420. DOI: 10.3390/cancers15051621.
Xiong T, Cao F, Zhu G, Ye X, Cui Y, Zhang H Adipocyte. 2022; 11(1):653-664.
PMID: 36415995 PMC: 9704414. DOI: 10.1080/21623945.2022.2148885.
Krausewitz P, Schmeller H, Luetkens J, Dabir D, Ellinger J, Ritter M World J Urol. 2022; 40(9):2239-2244.
PMID: 35833972 PMC: 9427866. DOI: 10.1007/s00345-022-04083-3.
Patient-reported outcomes associated with cancer screening: a systematic review.
Kim A, Chung K, Keir C, Patrick D BMC Cancer. 2022; 22(1):223.
PMID: 35232405 PMC: 8886782. DOI: 10.1186/s12885-022-09261-5.